Table 1.
Proteomic pathways associated with ARDS.
Pathway | Biomarker | Source | Role in ARDS | Reference |
---|---|---|---|---|
Endothelium injury and activation | VWF-Ag | Endothelial cells and platelets | Increase platelet binding to vascular endothelium | [17–22] |
Ang-2 | Endothelial cells | Regulates capillary permeability | [21,23–26] | |
ICAM-1 | Endothelial cells, type 1 alveolar cells, leukocytes | Promotes leukocyte binding and transmigration | [27–31] | |
E-selectin & P-selectin | Endothelial cells, platelets & leukocytes | Promotes leukocyte binding and transmigration | [32–34] | |
VEGF | Endothelial cells | Increases vascular permeability | [35–39] | |
Epithelial injury | SP-A & SP-D | Type II alveolar cells | Impaired alveolar recruitment and innate immunity | [40–43] |
RAGE | Type I epithelial cells | Receptor for inflammatory ligands | [44,45] | |
KL-6 | Type II epithelial cells | Increased expression in injury or repair | [46] | |
Inflammation | IL-6 | Leukocytes | Proinflammatory | [43,47–50] |
IL-8 | Leukocytes | Proinflammatory | [43,47–50] | |
IL-1β | Macrophages | Proinflammatory | [49] | |
TNF-α | Macrophages | Proinflammatory | [49,51,52] | |
sTNFr-I & II | Multiple tissues | Proinflammatory | [51–53] | |
Neutrophils | Vascular migration | Promote phagocytosis and cellular injury | [54–56] | |
MMP-9 | Neutrophils | Mediate neutrophil cellular injury | [57] | |
Macrophages | Resident in lung and vascular migration | Promote immunity and repair | [58] | |
GM-CSF | Leukocytes and endothelial cells | Promote immunity and repair | [59] | |
Coagulation | Protein C | Liver | Prevents in-situ thrombosis | [23,30,60] |
PAI-I | Vascular endothelial cells and platelets | Promotes thrombosis | [23,30,48,60–62] | |
Thrombomodulin | Type II pneumocytes | Activates protein C | [19,60] | |
Oxidative stress | Nitric oxide | Endothelial cells and leukocytes | Mediator of oxidative injury | [63] |
Ferritin | Acute phase reactant and product of oxidative stress | Mediator of oxidative injury | [64,65] | |
Antioxidants | Ubiquitous | Prevent oxidative injury | [66] | |
Fibrosis | PCP I & III | Fibroblasts | Marker of collagen synthesis | [67–69] |
Disordered repair | TGF-α | Ubiquitous | Endothelial cell migration and angiogenesis | [70,71] |
KGF & HGF | Mesenchymal cells | Epithelial cell mitogens | ||
Apoptosis | Fas/Fas ligand | Ubiquitous | Promote cell death | [72–74] |
Perforin/granzyme | Ubiquitous | Promote cell death | [74] | |
Extracellular matrix | Desmosine | Lung interstitium | Marker of disruption of extracellular matrix | [75,76] |
GM-CSF, granulocyte/macrophage colony stimulating factor; HGF, hepatocyte growth factor; ICAM-1, intercellular adhesion molecule 1; IL-1β, interleukin 1 beta; KGF, keratinocyte growth factor; PAI-I, plasminogen activator inhibitor-I; PCP I & III, procollagen peptides I & III; RAGE, receptor for advanced glycation end products; SPA & D, surfactant protein A & D; TGF-α transforming growth factor alpha; TNF-α, tumor necrosis factor alpha; vWF-Ag, von Willebrand factor antigen.